1831 related articles for article (PubMed ID: 28592285)
1. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
2. Specific blockade CD73 alters the "exhausted" phenotype of T cells in head and neck squamous cell carcinoma.
Deng WW; Li YC; Ma SR; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2018 Sep; 143(6):1494-1504. PubMed ID: 29663369
[TBL] [Abstract][Full Text] [Related]
3. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
[TBL] [Abstract][Full Text] [Related]
5. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.
Liu JF; Wu L; Yang LL; Deng WW; Mao L; Wu H; Zhang WF; Sun ZJ
J Exp Clin Cancer Res; 2018 Mar; 37(1):44. PubMed ID: 29506555
[TBL] [Abstract][Full Text] [Related]
6. A defect in KCa3.1 channel activity limits the ability of CD8
Chimote AA; Balajthy A; Arnold MJ; Newton HS; Hajdu P; Qualtieri J; Wise-Draper T; Conforti L
Sci Signal; 2018 Apr; 11(527):. PubMed ID: 29692361
[TBL] [Abstract][Full Text] [Related]
7. Cell surface markers for T and B lymphocytes activation and adhesion as putative prognostic biomarkers for head and neck squamous cell carcinoma.
Andrade MC; Ferreira SB; Gonçalves LC; De-Paula AM; de Faria ES; Teixeira-Carvalho A; Martins-Filho OA
Hum Immunol; 2013 Dec; 74(12):1563-74. PubMed ID: 23994583
[TBL] [Abstract][Full Text] [Related]
8. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis.
Wen YH; Lin HQ; Li H; Zhao Y; Lui VWY; Chen L; Wu XM; Sun W; Wen WP
Cancer Immunol Immunother; 2019 Feb; 68(2):221-232. PubMed ID: 30357458
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
10. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
[TBL] [Abstract][Full Text] [Related]
11. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
12. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.
Gadwa J; Bickett TE; Darragh LB; Knitz MW; Bhatia S; Piper M; Van Court B; Bhuvane S; Nguyen D; Nangia V; Kleczko EK; Nemenoff RA; Karam SD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789881
[TBL] [Abstract][Full Text] [Related]
13. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
[TBL] [Abstract][Full Text] [Related]
15. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
16. CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression.
Sun W; Li WJ; Wu CY; Zhong H; Wen WP
J Exp Clin Cancer Res; 2014 Apr; 33(1):35. PubMed ID: 24761979
[TBL] [Abstract][Full Text] [Related]
17. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Ma SR; Wang WM; Huang CF; Zhang WF; Sun ZJ
Oncotarget; 2015 Apr; 6(11):8807-21. PubMed ID: 25871396
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
Sitkovsky MV; Kjaergaard J; Lukashev D; Ohta A
Clin Cancer Res; 2008 Oct; 14(19):5947-52. PubMed ID: 18829471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
